This hypothesis is based on evidence that ductal carcinoma in situ has a higher frequency of HER2 gene amplification/overexpression (50-60%) compared to invasive breast cancer (20-30%) (27). This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.